Zhongsheng Group Holdings Limited

Equities

881

KYG9894K1085

Auto Vehicles, Parts & Service Retailers

Market Closed - Hong Kong Stock Exchange 03:08:20 2023-12-04 am EST Intraday chart for Zhongsheng Group Holdings Limited 5-day change 1st Jan Change
17.60 HKD +0.23% -4.66% -56.16%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Manufacturing Outlook Limits Asian Stock Markets MT
Tiantan Biological Products Secures Another Blood Collection License MT
Zhongsheng Pharmaceutical Gets Drug Registration Certificate for Carbocysteine Oral Solution MT
Middle East Turmoil, Crude Prices Roil Asian Markets in Holiday-Thinned Trading MT
Beijing Tiantan Biological Products Lands Blood Collection License in China’s Liping County MT
Zhongsheng Group's Profit Drops 12.8% in H1 MT
Zhongsheng Group Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Bargain Hunting Lifts Asian Stock Markets MT
Zhongsheng Pharmaceutical Gets Nod to Register Moxifloxacin Hydrochloride Eye Drops MT
Chairman, Controlling Shareholder Boosts Stake in Zhongsheng Group MT
Zhongsheng Group Holdings Limited commences an Equity Buyback Plan for 240,182,336 shares, representing 10% of its issued share capital, under the authorization approved on June 19, 2023. CI
Zhongsheng Pharma Registers Mucolytic in China MT
China Services Outlook Blunts Asian Stock Markets MT
Zhongsheng Pharmaceutical Unit Completes Phase III Clinical Trial of Flu Drug MT
Zhongsheng Group Slashes Conversion Price of HK$4.56 Billion Convertible Bonds MT
Zhongsheng Group Holdings Limited Approves Final Dividend for the Year Ended 31 December 2022, Payable on July 14, 2023 CI
Zhongsheng Group Holdings Limited's Equity Buyback announced on August 31, 2022, has expired. CI
Zhongsheng Pharma Enrols Subjects in Phase IIb Clinical Trial of NASH Drug MT
Zhongsheng Group Buys Back 10.2 Million Shares MT
Zhongsheng Group Holdings CEO Boosts Shareholding MT
Zhongsheng Pharm Unit Enrolls First Subject for RAY1225 Injection Trial MT
Zhongsheng Group Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2022 CI
Zhongsheng Group Partially Redeems 2025 Convertible Bonds MT
Zhongsheng Pharma Gets Conditional Market Approval For Oral COVID-19 Drug MT
Zhongsheng Group Holdings Limited Announces Change of Composition of Board Committees CI
Chart Zhongsheng Group Holdings Limited
More charts
Zhongsheng Group Holdings Limited is specialized in vehicle distribution. The group offers light luxury vehicles (Mercedes-Benz, Lexus, BMW, Audi, etc.) and medium and high-end vehicles (Toyota, Honda, Nissan, Volvo, Land Rover, etc.). Sales by activity are broken down as follows - new vehicle sales (81.4%): 528,154 units sold in 2021; - after-sales services (14%). In addition, the group offers the sale of accessories; - used car sales (4.6%): 139,413 units sold. At the end of 2021, Zhongsheng Group Holdings Limited has 412 dealerships in China. All sales are generated in China.
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
16.04CNY
Average target price
31.60CNY
Spread / Average Target
+96.97%
Consensus
  1. Stock
  2. Equities
  3. Stock Zhongsheng Group Holdings Limited - Hong Kong Stock Exchange
  4. News Zhongsheng Group Holdings Limited
  5. Zhongsheng Pharmaceutical Gets Nod to Register Moxifloxacin Hydrochloride Eye Drops
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer